Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinohio Research Services

Neither a doctor nor a teaching hospital

Research payments

$517,768

77 payments

Through program year 2025, Clinohio Research Services is reported as receiving $517,768 in research payments, across 77 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $169,113 24
2024 Research $102,258 18
2023 Research $83,710 21
2022 Research $18,698 9
2021 Research $8,257 2
2020 Research $64,215 2
2019 Research $71,516 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $235,594 38 payments
  2. E.R. Squibb & Sons, L.L.C. $193,821 11 payments
  3. Exeltis, USA Inc. $47,820 23 payments
  4. Amgen Inc. $26,724 4 payments
  5. Pfizer Inc. $13,809 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $197,080 31 payments
  2. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis $71,516 1 payment
  3. Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis $55,253 6 payments
  4. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod $41,110 1 payment
  5. LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women $34,840 16 payments
  6. Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) $24,941 2 payments
  7. M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $16,102 4 payments
  8. A Phase 2 Multicenter Randomized Doubleblind Placebocontrolled 16Week Study Evaluating the Safety and Efficacy of Ritlecitinib Pf06651600 in Adults With Moderate to Severe Hidradenitis Suppurativa $13,809 1 payment
  9. ASCEND P3 AD Extension $13,000 1 payment
  10. Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females $12,980 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record